10:52 EST Altimmune (ALT) sinks 21% to $3.98 after Phase 2b MASH data
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Balanced Risk-Reward for Altimmune’s Pemvidutide in a Crowded MASH Landscape Supports Hold Rating
- Altimmune reports positive Phase 2b pemvidutide MASH results
- Altimmune reports ‘positive’ results from IMPACT Phase 2b trial of pemvidutide
- Altimmune put volume heavy and directionally bearish
- Altimmune call volume above normal and directionally bullish